Compare Stocks: SMMT, MRK, LPA, and NTRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LPA Logistic Properties of the Americas	$3.12 +0.8%	$3.11	$2.04 ▼ $6.30	$98.50M	5.4	162,320 shs	15,133 shs
MRK Merck & Co., Inc.	$146.53 -0.4%	$137.99	$77.58 ▼ $156.92	$361.50B	0.21	10.66 million shs	6.04 million shs
NTRA Natera	$369.03 +0.7%	$303.46	$157.43 ▼ $369.69	$53.19B	1.54	1.35 million shs	1.38 million shs
SMMT Summit Therapeutics	$17.86 +0.8%	$14.66	$12.07 ▼ $29.23	$14.25B	-1.24	4.31 million shs	2.81 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LPA Logistic Properties of the Americas	+0.98%	+1.98%	-5.50%	-13.45%	-50.64%
MRK Merck & Co., Inc.	+1.68%	+1.82%	+8.85%	+29.18%	+81.62%
NTRA Natera	+6.07%	+12.32%	+17.52%	+58.29%	+108.81%
SMMT Summit Therapeutics	+2.43%	+4.24%	+38.22%	+28.87%	-2.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LPA Logistic Properties of the Americas	$3.12 +0.8%	$3.11	$2.04 ▼ $6.30	$98.50M	5.4	162,320 shs	15,133 shs
MRK Merck & Co., Inc.	$146.53 -0.4%	$137.99	$77.58 ▼ $156.92	$361.50B	0.21	10.66 million shs	6.04 million shs
NTRA Natera	$369.03 +0.7%	$303.46	$157.43 ▼ $369.69	$53.19B	1.54	1.35 million shs	1.38 million shs
SMMT Summit Therapeutics	$17.86 +0.8%	$14.66	$12.07 ▼ $29.23	$14.25B	-1.24	4.31 million shs	2.81 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LPA Logistic Properties of the Americas	+0.98%	+1.98%	-5.50%	-13.45%	-50.64%
MRK Merck & Co., Inc.	+1.68%	+1.82%	+8.85%	+29.18%	+81.62%
NTRA Natera	+6.07%	+12.32%	+17.52%	+58.29%	+108.81%
SMMT Summit Therapeutics	+2.43%	+4.24%	+38.22%	+28.87%	-2.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LPA Logistic Properties of the Americas	2.00	Hold	$7.50	140.77% Upside
MRK Merck & Co., Inc.	2.71	Moderate Buy	$154.24	5.26% Upside
NTRA Natera	2.83	Moderate Buy	$330.83	-10.35% Downside
SMMT Summit Therapeutics	2.47	Hold	$25.91	45.06% Upside

Current Analyst Ratings Breakdown

Latest SMMT, MRK, LPA, and NTRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	MRK Merck & Co., Inc.	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$150.00 ➝ $172.00
9/9/2026	SMMT Summit Therapeutics	Summit Redstone Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
9/9/2026	MRK Merck & Co., Inc.	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$127.00 ➝ $161.00
9/9/2026	NTRA Natera	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$290.00 ➝ $435.00
9/8/2026	SMMT Summit Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$33.00
9/8/2026	NTRA Natera	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$385.00
9/8/2026	NTRA Natera	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform ➝ Buy
9/8/2026	MRK Merck & Co., Inc.	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$146.00 ➝ $170.00
9/8/2026	NTRA Natera	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$385.00
9/4/2026	MRK Merck & Co., Inc.	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$150.00 ➝ $170.00
9/3/2026	SMMT Summit Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral

(Data available from 9/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LPA Logistic Properties of the Americas	$50.13M	1.96	$0.37 per share	8.40	$10.27 per share	0.30
MRK Merck & Co., Inc.	$65.01B	5.56	$11.55 per share	12.69	$21.22 per share	6.91
NTRA Natera	$2.31B	23.07	N/A	N/A	$12.38 per share	29.81
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	$0.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LPA Logistic Properties of the Americas	$10.50M	N/A	5.77	14.16	N/A	30.97%	0.46%	0.21%	11/11/2026 (Estimated)
MRK Merck & Co., Inc.	$18.25B	$1.25	117.22	15.17	6.31	4.77%	16.73%	6.13%	10/29/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.36	N/A	36,903.40	N/A	-7.11%	-11.38%	-7.87%	11/5/2026 (Estimated)
SMMT Summit Therapeutics	-$1.08B	-$1.12	N/A	N/A	N/A	N/A	-168.94%	-141.92%	10/19/2026 (Estimated)

Latest SMMT, MRK, LPA, and NTRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	LPA Logistic Properties of the Americas	$0.04	$0.40	+$0.36	$0.40	$14.14 million	$14.74 million
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
8/4/2026	Q2 2026	MRK Merck & Co., Inc.	-$0.26	-$0.13	+$0.13	-$0.54	$16.37 billion	$16.61 billion
7/23/2026	Q2 2026	SMMT Summit Therapeutics	-$0.2744	-$0.28	-$0.0056	-$0.28	$0.11 million	N/A
6/30/2026	Q2 2026	LPA Logistic Properties of the Americas	N/A	$0.40	N/A	$0.40	N/A	$14.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LPA Logistic Properties of the Americas	N/A	N/A	N/A	N/A	N/A
MRK Merck & Co., Inc.	$3.40	2.32%	+5.75%	272.00%	14 Years
NTRA Natera	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest SMMT, MRK, LPA, and NTRA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/29/2026	MRK Merck & Co., Inc.	quarterly	$0.85	2.36%	9/15/2026	9/15/2026	10/7/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LPA Logistic Properties of the Americas	0.91	1.80	1.80
MRK Merck & Co., Inc.	1.22	1.32	1.10
NTRA Natera	N/A	3.00	2.85
SMMT Summit Therapeutics	N/A	6.96	6.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LPA Logistic Properties of the Americas	42.71%
MRK Merck & Co., Inc.	76.07%
NTRA Natera	99.90%
SMMT Summit Therapeutics	4.61%

Insider Ownership

Company	Insider Ownership
LPA Logistic Properties of the Americas	32.00%
MRK Merck & Co., Inc.	0.17%
NTRA Natera	5.05%
SMMT Summit Therapeutics	83.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LPA Logistic Properties of the Americas	36	31.62 million	21.50 million	N/A
MRK Merck & Co., Inc.	75,000	2.47 billion	2.46 billion	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable
SMMT Summit Therapeutics	265	797.75 million	131.63 million	Optionable

SMMT, MRK, LPA, and NTRA Headlines

Recent News About These Companies

Summit Therapeutics: It's Okay Not To Have An Answer

September 17 at 9:32 AM | seekingalpha.com

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Azenta (AZTA)

September 15 at 6:31 PM | theglobeandmail.com

Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 7% - Should You Sell?

September 15 at 3:39 PM | marketbeat.com

Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients

September 15 at 7:00 AM | businesswire.com

Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer

September 13, 2026 | streetinsider.com

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso ...

September 13, 2026 | streetinsider.com

Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial

September 13, 2026 | msn.com

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu

September 13, 2026 | gurufocus.com

September 13, 2026 | businesswire.com

Hsbc Holdings PLC Purchases Shares of 120,560 Summit Therapeutics PLC $SMMT

September 12, 2026 | marketbeat.com

Summit Therapeutics PLC (SMMT)

September 10, 2026 | fr.investing.com

Summit Therapeutics Shares Rise After Upgrade From Jefferies

September 9, 2026 | marketscreener.comM

Summit Therapeutics shares gain after Jefferies upgrades stock to buy

September 9, 2026 | msn.com

Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Time to Buy?

September 9, 2026 | marketbeat.com

Summit Therapeutics PLC $SMMT Shares Bought by Wellington Management Group LLP

September 9, 2026 | marketbeat.com

Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab

September 8, 2026 | insidermonkey.com

Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress

September 7, 2026 | insidermonkey.com

Seven Fleet Capital Management LP Acquires Shares of 73,300 Summit Therapeutics PLC $SMMT

September 5, 2026 | marketbeat.com

Bank of New York Mellon Corp Takes $6.28 Million Position in Summit Therapeutics PLC $SMMT

September 5, 2026 | marketbeat.com

Summit Therapeutics (NASDAQ:SMMT) Raised to Hold at Wall Street Zen

September 5, 2026 | marketbeat.com

SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China

September 4, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SMMT, MRK, LPA, and NTRA Company Descriptions

Logistic Properties of the Americas NYSEAMERICAN:LPA

$3.12 +0.03 (+0.81%)

Closing price 03:59 PM Eastern

Extended Trading

$3.12 +0.01 (+0.32%)

As of 04:10 PM Eastern

Logistic Properties of the Americas develops, builds and operates logistic real estate properties. It operates through the following geographical segments: Colombia, Peru, and Costa Rica. The company is headquartered in Miami, FL.

Merck & Co., Inc. NYSE:MRK

$146.52 -0.63 (-0.42%)

Closing price 03:59 PM Eastern

Extended Trading

$146.96 +0.44 (+0.30%)

As of 04:18 PM Eastern

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Natera NASDAQ:NTRA

$369.03 +2.72 (+0.74%)

Closing price 03:59 PM Eastern

Extended Trading

$369.20 +0.16 (+0.04%)

As of 04:17 PM Eastern

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Summit Therapeutics NASDAQ:SMMT

$17.86 +0.14 (+0.79%)

Closing price 03:59 PM Eastern

Extended Trading

$17.79 -0.07 (-0.39%)

As of 04:17 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SMMT, MRK, LPA, and NTRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SMMT, MRK, LPA, and NTRA Earnings

Compare Dividends

Latest SMMT, MRK, LPA, and NTRA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SMMT, MRK, LPA, and NTRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SMMT, MRK, LPA, and NTRA Company Descriptions

Logistic Properties of the Americas NYSEAMERICAN:LPA

Merck & Co., Inc. NYSE:MRK

Natera NASDAQ:NTRA

Summit Therapeutics NASDAQ:SMMT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools